|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Other high-risk cancer genes that confer increased risks of breast or ovarian cancer in addition to other cancers include the hereditary non-polyposis colorectal cancer genes and the TP53 gene, which causes breast cancer as part of the Li-Fraumeni syndrome.
|
7547224 |
1995 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These results support previous data showing that around 50% of OCs have mutations in TP53 and in addition, suggest that MDM2 is not amplified in OC, but the presence of sarcomatous features in mixed müllerian tumours may result in positive immunohistochemistry with IF-2.
|
7547235 |
1995 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
An abundance of p53 null mutations in ovarian carcinoma.
|
8700537 |
1996 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Loss of heterozygosity on chromosome 5q in ovarian cancer is frequently accompanied by TP53 mutation and identifies a tumour suppressor gene locus at 5q13.1-21.
|
8679443 |
1996 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Both p53 and Bcl-2 were found to be independent prognostic indicators of survival in ovarian cancer.
|
8616869 |
1996 |
|
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
DNA ploidy and MYC DNA amplification in ovarian carcinomas. Correlation with p53 and bcl-2 expression, proliferative activity and prognosis.
|
8972757 |
1996 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
In conclusion, the present results are consistent with a role of p53 as a determinant of chemosensitivity of ovarian carcinoma.
|
8630996 |
1996 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Subcellular localization of accumulated p53 in ovarian cancer cells.
|
8626145 |
1996 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Poor correlation with loss of heterozygosity on chromosome 17p and p53 mutations in ovarian cancers.
|
8910623 |
1996 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These findings demonstrate the potential of the p53 tumor suppressor gene therapy in human ovarian carcinoma.
|
8622881 |
1996 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
These results strongly suggest that disseminated serous carcinomas, whether primary in the ovary, endometrium, or peritoneum, are of monoclonal rather than multicentric origin; that bilateral stage III ovarian cancers are typically of monoclonal origin; and that additional genetic events involving p53 might occur during progression of these tumors.
|
8685209 |
1996 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Detection of cellular heterogeneity by DNA ploidy, 17 chromosome, and p53 gene in primary carcinoma and metastasis in a case of ovarian cancer.
|
8852451 |
1996 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
96 of the ovarian carcinoma cases had been previously examined for mutations in TP53 and/or for overexpression of the TP53 protein.
|
9038623 |
1996 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Taken together, these observations support a role for mutations of the p53 gene in the development of cisplatin resistance in ovarian cancer as a consequence of loss of the ability of p53 to transactivate bax, an apoptosis-inducing gene.
|
8564971 |
1996 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Ovarian cancer genomic instability correlates with p53 frameshift mutations.
|
9067268 |
1997 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The present study was undertaken to investigate the prognostic and predictive role of p53 alterations in ovarian cancer.
|
9010031 |
1997 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Discordance in p53 mutations when comparing ascites and solid tumors from patients with serous ovarian cancer.
|
9143413 |
1997 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These data confirm the findings of previous investigations describing TP53 mutation in ovarian carcinoma and demonstrate that archival paraffin-embedded tissues can be used for such analyses.
|
9301456 |
1997 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Expression of the p53 induced tumor suppressor p21waf1/cip1 in ovarian carcinomas: correlation with p53 and Ki-67 immunohistochemistry.
|
9100069 |
1997 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These findings may have important ramifications in the choice of wild-type p53 genotype for gene replacement therapy of ovarian cancer.
|
9253509 |
1997 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
|
9563008 |
1997 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutant p53 is frequently detected in endometrial and ovarian carcinoma, but it is rare in cervical cancers.
|
9546366 |
1998 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Therefore, current estimates of TP53 alterations in ovarian cancer may be inaccurate.
|
9579562 |
1998 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
To characterize the involvement of the TP53 tumor suppressor gene in ovarian cancer, mutation analysis of exons 2-11 of TP53 and immunodetection of its protein product, p53, were done in 48 ovarian tumors.Normally, p53 is not immunodetectable.
|
9723023 |
1998 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations of the p53 gene were observed in 44% of ovarian cancers; p53 gene status did not relate to telomerase activity.
|
9540942 |
1998 |